多発性骨髄腫におけるCELMOD剤の役割
PubMedで要約を見る
まとめ
この要約は機械生成です。新しいCELMoD剤であるイベルドミドとメジグドミドは,再発性または耐性多発性骨髄腫の治療に有望である. これらの標的型タンパク質分解剤は,現在の治療法に耐性のある患者に新しい選択肢を提供することができる.
科学分野
- 腫瘍学
- 薬理学について
- 生物化学
背景
- 多発性骨髄腫はほとんど治癒できず,ほとんどの患者は再発または治療抵抗性を経験します.
- 新しい治療法,特に再発性または耐性多発性骨髄腫の需要は満たされていない.
- 標的型タンパク質の分解は 骨髄腫の薬効性標的を拡大するための有望な方法である.
研究 の 目的
- 多発性骨髄腫の新たな治療法としてのイベルドミドとメジドミドの可能性を評価する.
- 既存の治療法に対する耐性を含む臨床前モデルのCELMoD剤の有効性を評価する.
- イベルドミドとメジグドミドの安全性および耐受性のプロフィールを臨床用途で調べる.
主な方法
- レナリドミドとポマリドミドに抵抗する細胞系を用いた臨床前評価.
- マウスモデルでの多発性骨髄腫の評価
- 特殊性,効力,安全性に関する分析
主要な成果
- 臨床前データは,イベルドミドとメジドミドがレナリドミドとポマリドミド耐性モデルでも有効であることを示唆しています.
- これらの薬剤は,最適化された特異性,効能,および安全性を示しています.
- 他の骨髄腫治療法との相乗効果の可能性があることが観察されました.
結論
- イベルドミドとメジグドミドは再発性または耐性多発性骨髄腫に対する有望な経口CELMoD剤です.
- イベルドミドは早期の治療や維持治療に適し,メジドミドは早期に再発した患者や以前の治療を受けた患者にとって有益である.
- 現在進行中の臨床試験では これらの薬剤を評価しており,初期結果は有望である.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

